Biosimilars Watchlist

Drug status

Sandoz — Erelzi (Enbrel)

Court upholds Enbrel patents and a Sandoz is appealing.

Mylan — Ogivri (Herceptin)

Launched November 29, 2019

Teva/Celltrion — Herzuma (Herceptin)

Approved - most likely will launch in 1H2020

Merck/Samsung Bioepis — Ontruzant (Herceptin)

Approved - most likely will launch in 1H2020

Pfizer — Trazimera (Herceptin)

Launched February 15, 2020

Pfizer — Zirabev (Avastin)

Launched December 31, 2019

Pfizer — Ruxience (Rituxan)

Launched January 2020

Teva — Truxima (Rituxan)

Launched November 11, 2019

Tanvex — (Neupogen)

Received CRL from FDA

Sandoz — Ziextenzo (Neulasta)

Launched November 18, 2019